Carcinotech manufactures 3D printed living tumors that accurately replicate human tumor biology, providing researchers with precise models for cancer studies. This technology enhances drug testing efficacy and supports the development of personalized treatment strategies, overcoming the limitations of conventional cancer research methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer research methods often rely on models that do not accurately replicate the complexity and heterogeneity of human tumors. This can lead to inaccurate drug testing results and hinder the development of effective, personalized treatment strategies.
Solution
Carcinotech provides 3D-bioprinted, patient-derived tumor models that closely mimic the native tumor microenvironment. These models offer a physiologically relevant platform for oncology drug discovery and preclinical testing, enhancing the accuracy and predictability of research outcomes. Carcinotech also offers biopsy sourcing and a range of oncology assay services, providing an end-to-end solution for advancing cancer treatment breakthroughs. By using these advanced models, researchers can accelerate the identification of promising therapies and improve personalized treatment decisions.
Target Audience
The primary customers are researchers and drug developers in the oncology field, specifically those involved in early drug discovery, preclinical testing, and personalized medicine.
Features
- 3D-bioprinted tumors derived from patient biopsies, preserving the native microenvironment
- Extensive repository of diverse and characterized tumor biopsies
- Capability to incorporate over 20 different cell types within printed tumor models
- End-to-end preclinical oncology services, including biopsy sourcing, tumor development, and oncology assays
- Models suitable for various treatment modalities, including immunotherapies, chemotherapies, and targeted therapies
- Application notes and case studies available to guide the use of Carcinotech models